Sonrgy

Sonrgy was a preclinical-stage biotechnology company that specialized in the development of ultrasound-triggered drug delivery systems for oncology. The company's core technology involved the use of nanocapsules designed to encapsulate potent chemotherapeutic agents, such as doxorubicin, and release them only when triggered by localized ultrasound at the tumor site. This approach was intended to increase the therapeutic index of cancer drugs by concentrating the treatment within the tumor while reducing systemic exposure and associated toxicities. Based in San Diego and founded by researchers from the University of California, San Diego, Sonrgy focused on addressing hard-to-treat solid tumors, including pancreatic and ovarian cancers. Although the company made significant strides in preclinical development with support from federal grants, it is currently inactive.